NuPeak Therapeutics

Publications

Our publications provide a comprehensive background for the discoveries of the drug target and product.

MAPK13 controls structural remodeling and disease after epithelial injury

Wu K, Zhang Y, Mao D, Iberg C, Yin-Declue H, Sun K, Keeler S, Wikfors H, Young D, Yantis J, Austin S, Byers D, Brody S, Crouch E, Romero A, and Holtzman M. MAPK13 controls structural remodeling and disease after epithelial injury. bioRxiv. 2024;10.1101/2024.05.31.596863:doi.org/10.1101/2024.05.31.596863.

The post-viral GPNMB+ immune niche persists in long-term Covid, asthma, and COPD. medRxiv.

Wu K, Zhang Y, Yin Declue H, Sun K, Mao D, Crouch EC, Byers DE, and Holtzman MJ. The post-viral GPNMB+ immune niche persists in long-term Covid, asthma, and COPD. medRxiv. 2024;2024.08.27.24312640:doi: 10.1101/2024.08.27.24312640.

A correctable immune niche for basal-epithelial stem cell reprogramming and post-viral lung diseases.

Wu K, Zhang Y, Yin-Declue H, Sun K, Mao D, Austin S, Crouch E, Brody S, Byers D, Hoffmann C, Hughes M, and Holtzman M. A correctable immune niche for basal-epithelial stem cell reprogramming and post-viral lung diseases. J Clin Invest. 2024;134:e183092.

A potent MAPK13-14 inhibitor prevents airway inflammation and mucus production.

Keeler SP, Wu K, Zhang Y, Mao D, Li M, Iberg CA, Austin SP, Glaser SA, Yantis J, Podgorny S, Brody SL, Chartock JR, Han Z, Byers DE, Romero AG, and Holtzman MJ. A potent MAPK13-14 inhibitor prevents airway inflammation and mucus production. Am J Physiol Lung Cell Mol Physiol. 2023;325:L726-40.

Lung remodeling regions in long-term coronavirus disease 2019 feature basal epithelial cell reprogramming.

Wu K, Zhang Y, Yin Declue H, Austin SR, Byers DE, Crouch EC, and Holtzman MJ. Lung remodeling regions in long-term coronavirus disease 2019 feature basal epithelial cell reprogramming. Am J Pathol 2023;193:680-9.

Basal-epithelial stem cells cross an alarmin checkpoint for post-viral lung disease.

Wu K, Kamimoto K, Zhang Y, Yang K, Keeler SP, Gerovac BJ, Agapov EV, Austin SP, Yantis J, Gissy KA, Byers DE, Alexander-Brett J, Hoffmann CM, Wallace M, Hughes ME, Morris SA, and Holtzman MJ. Basal-epithelial stem cells cross an alarmin checkpoint for post-viral lung disease. J Clin Invest. 2021;131:e149336.

TLR3-activated monocyte-derived dendritic cells trigger progression from acute viral infection to chronic disease in the lung.

Wang X, Wu K, Keeler SP, Mao D, Agapov EV, Zhang Y, and Holtzman MJ. TLR3-activated monocyte-derived dendritic cells trigger progression from acute viral infection to chronic disease in the lung. J Immunol. 2021;206:1297-314 (selected for Top-Reads p. 115).

Group 2 innate lymphoid cells must partner with the myeloid-macrophage lineage for long-term postviral lung disease.

Wu K, Wang X, Keeler SP, Gerovac BJ, Agapov E, Byers DE, Gilfillan S, Colonna M, Zhang Y, and Holtzman MJ. Group 2 innate lymphoid cells must partner with the myeloid-macrophage lineage for long-term postviral lung disease. J Immunol. 2020;205:1084-101.

Influenza A virus infection causes chronic lung disease linked to sites of active viral RNA remnants.

Keeler SP, Agapov EV, Hinojosa ME, Letvin AN, Wu K, and Holtzman MJ. Influenza A virus infection causes chronic lung disease linked to sites of active viral RNA remnants. J Immunol. 2018;201:2354-68.

Triggering receptor expressed on myeloid cells-2 (TREM-2) expression tracks with M2-like macrophage activity and disease severity in COPD.

Byers DE, Wu K, Dang-Vu G, Jin X, Agapov E, Zhang X, Battaile JT, Schechtman KB, Yusen R, Pierce RA, and Holtzman MJ. Triggering receptor expressed on myeloid cells-2 (TREM-2) expression tracks with M2-like macrophage activity and disease severity in COPD. Chest. 2018;153:77-86.

TREM-2 promotes macrophage survival and lung disease after respiratory viral infection.

Wu K, Byers DE, Jin X, Agapov E, Alexander-Brett J, Patel AC, Cella M, Gilfilan S, Colonna M, Kober DL, Brett TJ, and Holtzman MJ. TREM-2 promotes macrophage survival and lung disease after respiratory viral infection. J Exp Med. 2015;212:681-97.

Long-term IL-33-producing epithelial progenitor cells in chronic obstructive lung disease.

Byers DE, Alexander-Brett J, Patel AC, Agapov E, Dang-Vu G, Jin X, Wu K, You Y, Alevy YG, Girard J-P, Stappenbeck TS, Patterson GA, Pierce RA, Brody SL, and Holtzman MJ. Long-term IL-33-producing epithelial progenitor cells in chronic obstructive lung disease. J Clin Invest. 2013;123:3967-82.

IL-13–induced airway mucus production is attenuated by MAPK13 inhibition.

Alevy Y, Patel AC, Romero AG, Patel DA, Tucker J, Roswit WT, Miller CA, Heier RF, Byers DE, Brett TJ, and Holtzman MJ. IL-13–induced airway mucus production is attenuated by MAPK13 inhibition. J Clin Invest. 2012;122:4555-68.

Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease.

Kim EY, Battaile JT, Patel AC, You Y, Agapov E, Grayson MH, Benoit LA, Byers DE, Alevy Y, Tucker J, Swanson S, Tidwell R, Tyner JW, Morton JD, Castro M, Polineni D, Patterson GA, Schwendener RA, Allard JD, Peltz G, and Holtzman MJ. Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease. Nat Med. 2008;14:633-40.